» Articles » PMID: 33178490

Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care

Overview
Journal J Eur CME
Specialty Medical Education
Date 2020 Nov 12
PMID 33178490
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Mobile health (mHealth) technologies such as smartphone applications are increasingly being adopted in the healthcare setting to support the delivery of evidence-based care. Given the approaching ubiquity of mHealth tools in medical practice, it is incumbent on the continuing medical education (CME) community to understand how these tools can be leveraged to develop clinician knowledge and competence, and how we can assess these educational outcomes. In this report, we describe our experience developing and incorporating a mobile decision-support tool into multiple activity formats within the European Immuno-Oncology Clinic Companion CME initiative.

Citing Articles

Mobile-linked point-of-care diagnostics in community-based healthcare: a scoping review of user experiences.

Nxele S, Moetlhoa B, Dlangalala T, Maluleke K, Kgarosi K, Theberge A Arch Public Health. 2024; 82(1):139.

PMID: 39192369 PMC: 11348575. DOI: 10.1186/s13690-024-01376-4.


PubMed4Hh: A Point-of-Care Mobile App for Evidence-Based Clinical Decision Support for Nurse Residents in Maryland.

Gartrell K, Warren J, Fontelo P Comput Inform Nurs. 2023; 41(12):983-992.

PMID: 38062547 PMC: 10746293. DOI: 10.1097/CIN.0000000000001063.


Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.

Pescia C, Guerini-Rocco E, Viale G, Fusco N Cancers (Basel). 2023; 15(22).

PMID: 38001690 PMC: 10670146. DOI: 10.3390/cancers15225430.

References
1.
Brahmer J, Lacchetti C, Thompson J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018; 14(4):247-249. DOI: 10.1200/JOP.18.00005. View

2.
Tarricone R, Cucciniello M, Armeni P, Petracca F, Desouza K, Hall L . Mobile Health Divide Between Clinicians and Patients in Cancer Care: Results From a Cross-Sectional International Survey. JMIR Mhealth Uhealth. 2019; 7(9):e13584. PMC: 6754682. DOI: 10.2196/13584. View

3.
Zon R, Edge S, Page R, Frame J, Lyman G, Omel J . American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology. J Oncol Pract. 2017; 13(3):207-210. DOI: 10.1200/JOP.2016.019836. View

4.
Da L, Teng Y, Wang N, Zaguirre K, Liu Y, Qi Y . Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2020; 10:1671. PMC: 7002539. DOI: 10.3389/fphar.2019.01671. View

5.
Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv119-iv142. DOI: 10.1093/annonc/mdx225. View